Investors & Media


resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases.

Strong scientific evidence suggests that aging is regulated by specific biochemical pathways. Medicines that target these biochemical pathways, such as the TORC1 pathway, may prevent or treat a variety of aging related diseases. resTORbio’s lead clinical program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including neurologic function. Inhibition of TORC1 has the potential to improve the function of aging organ systems and address multiple aging-related diseases.


Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Webcast & Replays
More information is coming soon.
IR & Media Contacts
Email Alerts